Matches in SemOpenAlex for { <https://semopenalex.org/work/W4384154127> ?p ?o ?g. }
- W4384154127 abstract "Abstract IMPORTANCE Treatment options for coronavirus disease 2019 (COVID-19) that can be used irrespective of risk factors for severe disease are warranted. OBJECTIVE To assess the efficacy and safety of ensitrelvir in patients with mild-to-moderate COVID-19. DESIGN The phase 3 part of a phase 2/3, double-blind, randomized, placebo-controlled study conducted from February 10 to July 10, 2022. SETTING A multicenter study conducted at 92 institutions in Japan, Vietnam, and South Korea. PARTICIPANTS Patients (aged 12 to <70 years) with mild-to-moderate COVID-19 within 120 hours of positive viral testing. INTERVENTIONS Patients were randomized (1:1:1) to receive once-daily ensitrelvir 125 mg (375 mg on day 1), 250 mg (750 mg on day 1), or placebo for 5 days. Among 1821 randomized patients, 1030 (347, 340, and 343 in the ensitrelvir 125-mg, ensitrelvir 250-mg, and placebo groups, respectively) were randomized in less than 72 hours of disease onset and assessed as the primary analysis population. MAIN OUTCOMES AND MEASURES The primary end point was the time to resolution of five COVID-19 symptoms (stuffy or runny nose, sore throat, cough, feeling hot or feverish, and low energy or tiredness). Other end points included virologic efficacy and safety. RESULTS The mean age was 35.7, 35.3, and 34.7 years, and 193 (55.6%), 185 (54.4%), and 174 (50.7%) patients were men in the ensitrelvir 125-mg, ensitrelvir 250-mg, and placebo groups, respectively (intention-to-treat, primary analysis population). A significant difference (P=.04 with a Peto-Prentice generalized Wilcoxon test stratified by vaccination history) was observed in the primary end point between ensitrelvir 125 mg and placebo in the primary analysis population (difference in median, −24.3 hours; 95% confidence interval, −78.7 to 11.7). Viral RNA levels on day 4 and time to negative viral titer demonstrated significant reduction vs placebo. The incidence of adverse events was 44.2%, 53.6%, and 24.8% in the ensitrelvir 125-mg, ensitrelvir 250-mg, and placebo groups, respectively. No treatment-related serious adverse events were reported. CONCLUSIONS AND RELEVANCE Treatment with ensitrelvir 125 mg demonstrated clinical and antiviral efficacy without new safety concerns. Generalizability to non-Asian populations should be confirmed. TRIAL REGISTRATION Japan Registry of Clinical Trials identifier: jRCT2031210350 . Key Points Question Can ensitrelvir, an oral severe acute respiratory syndrome coronavirus 2 3C-like protease inhibitor, shorten the duration of symptoms in patients with mild-to-moderate COVID-19 irrespective of risk factors for severe disease? Findings In this phase 3 part of a phase 2/3, double-blind, randomized study SCORPIO-SR, a statistically significant difference was observed in the time to resolution of five COVID-19 symptoms between ensitrelvir 125 mg and placebo in patients randomized in less than 72 hours of disease onset. Viral RNA and viral titer demonstrated significant reduction vs placebo. Meaning Ensitrelvir 125 mg treatment shortened time to resolution of key COVID-19 symptoms." @default.
- W4384154127 created "2023-07-14" @default.
- W4384154127 creator A5006534529 @default.
- W4384154127 creator A5021209820 @default.
- W4384154127 creator A5026347948 @default.
- W4384154127 creator A5028399560 @default.
- W4384154127 creator A5054162835 @default.
- W4384154127 creator A5062043309 @default.
- W4384154127 creator A5064348151 @default.
- W4384154127 creator A5067354013 @default.
- W4384154127 creator A5071159100 @default.
- W4384154127 creator A5079426665 @default.
- W4384154127 creator A5080236086 @default.
- W4384154127 creator A5088557295 @default.
- W4384154127 creator A5091026051 @default.
- W4384154127 date "2023-07-13" @default.
- W4384154127 modified "2023-10-10" @default.
- W4384154127 title "Efficacy and Safety of 5-Day Oral Ensitrelvir for Patients With Mild-to-Moderate COVID-19: The SCORPIO-SR Randomized Clinical Trial" @default.
- W4384154127 cites W3027630905 @default.
- W4384154127 cites W4200051875 @default.
- W4384154127 cites W4210665241 @default.
- W4384154127 cites W4224950216 @default.
- W4384154127 cites W4225286967 @default.
- W4384154127 cites W4226192094 @default.
- W4384154127 cites W4226236384 @default.
- W4384154127 cites W4280630418 @default.
- W4384154127 cites W4280650748 @default.
- W4384154127 cites W4282935642 @default.
- W4384154127 cites W4286009139 @default.
- W4384154127 cites W4295358187 @default.
- W4384154127 cites W4297785714 @default.
- W4384154127 cites W4297876464 @default.
- W4384154127 cites W4308179770 @default.
- W4384154127 cites W4308975290 @default.
- W4384154127 cites W4310957849 @default.
- W4384154127 cites W4311557154 @default.
- W4384154127 cites W4311983095 @default.
- W4384154127 cites W4312134853 @default.
- W4384154127 cites W4316034767 @default.
- W4384154127 cites W4319455345 @default.
- W4384154127 cites W4321748171 @default.
- W4384154127 doi "https://doi.org/10.1101/2023.07.11.23292264" @default.
- W4384154127 hasPublicationYear "2023" @default.
- W4384154127 type Work @default.
- W4384154127 citedByCount "1" @default.
- W4384154127 countsByYear W43841541272023 @default.
- W4384154127 crossrefType "posted-content" @default.
- W4384154127 hasAuthorship W4384154127A5006534529 @default.
- W4384154127 hasAuthorship W4384154127A5021209820 @default.
- W4384154127 hasAuthorship W4384154127A5026347948 @default.
- W4384154127 hasAuthorship W4384154127A5028399560 @default.
- W4384154127 hasAuthorship W4384154127A5054162835 @default.
- W4384154127 hasAuthorship W4384154127A5062043309 @default.
- W4384154127 hasAuthorship W4384154127A5064348151 @default.
- W4384154127 hasAuthorship W4384154127A5067354013 @default.
- W4384154127 hasAuthorship W4384154127A5071159100 @default.
- W4384154127 hasAuthorship W4384154127A5079426665 @default.
- W4384154127 hasAuthorship W4384154127A5080236086 @default.
- W4384154127 hasAuthorship W4384154127A5088557295 @default.
- W4384154127 hasAuthorship W4384154127A5091026051 @default.
- W4384154127 hasBestOaLocation W43841541271 @default.
- W4384154127 hasConcept C126322002 @default.
- W4384154127 hasConcept C141071460 @default.
- W4384154127 hasConcept C142724271 @default.
- W4384154127 hasConcept C168563851 @default.
- W4384154127 hasConcept C197934379 @default.
- W4384154127 hasConcept C203092338 @default.
- W4384154127 hasConcept C204787440 @default.
- W4384154127 hasConcept C27081682 @default.
- W4384154127 hasConcept C2777870961 @default.
- W4384154127 hasConcept C2778311950 @default.
- W4384154127 hasConcept C2779134260 @default.
- W4384154127 hasConcept C2908647359 @default.
- W4384154127 hasConcept C3008058167 @default.
- W4384154127 hasConcept C524204448 @default.
- W4384154127 hasConcept C535046627 @default.
- W4384154127 hasConcept C71924100 @default.
- W4384154127 hasConcept C99454951 @default.
- W4384154127 hasConceptScore W4384154127C126322002 @default.
- W4384154127 hasConceptScore W4384154127C141071460 @default.
- W4384154127 hasConceptScore W4384154127C142724271 @default.
- W4384154127 hasConceptScore W4384154127C168563851 @default.
- W4384154127 hasConceptScore W4384154127C197934379 @default.
- W4384154127 hasConceptScore W4384154127C203092338 @default.
- W4384154127 hasConceptScore W4384154127C204787440 @default.
- W4384154127 hasConceptScore W4384154127C27081682 @default.
- W4384154127 hasConceptScore W4384154127C2777870961 @default.
- W4384154127 hasConceptScore W4384154127C2778311950 @default.
- W4384154127 hasConceptScore W4384154127C2779134260 @default.
- W4384154127 hasConceptScore W4384154127C2908647359 @default.
- W4384154127 hasConceptScore W4384154127C3008058167 @default.
- W4384154127 hasConceptScore W4384154127C524204448 @default.
- W4384154127 hasConceptScore W4384154127C535046627 @default.
- W4384154127 hasConceptScore W4384154127C71924100 @default.
- W4384154127 hasConceptScore W4384154127C99454951 @default.
- W4384154127 hasLocation W43841541271 @default.
- W4384154127 hasOpenAccess W4384154127 @default.
- W4384154127 hasPrimaryLocation W43841541271 @default.
- W4384154127 hasRelatedWork W145735164 @default.
- W4384154127 hasRelatedWork W2036880761 @default.